BNP Paribas Financial Markets Decreases Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)

BNP Paribas Financial Markets cut its position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 85.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,300 shares of the company’s stock after selling 18,665 shares during the quarter. BNP Paribas Financial Markets’ holdings in ArriVent BioPharma were worth $88,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Novo Holdings A S boosted its stake in shares of ArriVent BioPharma by 1.0% in the fourth quarter. Novo Holdings A S now owns 1,520,627 shares of the company’s stock valued at $40,510,000 after purchasing an additional 15,312 shares during the period. Vanguard Group Inc. boosted its stake in ArriVent BioPharma by 5.3% during the 4th quarter. Vanguard Group Inc. now owns 1,417,291 shares of the company’s stock valued at $37,757,000 after acquiring an additional 71,741 shares during the last quarter. Northern Trust Corp boosted its stake in ArriVent BioPharma by 4.6% during the 4th quarter. Northern Trust Corp now owns 241,009 shares of the company’s stock valued at $6,420,000 after acquiring an additional 10,498 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in ArriVent BioPharma by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 206,379 shares of the company’s stock valued at $5,498,000 after acquiring an additional 4,011 shares during the last quarter. Finally, Barclays PLC boosted its stake in ArriVent BioPharma by 28.8% during the 4th quarter. Barclays PLC now owns 53,499 shares of the company’s stock valued at $1,425,000 after acquiring an additional 11,977 shares during the last quarter. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on AVBP shares. HC Wainwright increased their price objective on shares of ArriVent BioPharma from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th. Guggenheim began coverage on shares of ArriVent BioPharma in a report on Monday, March 10th. They set a “buy” rating and a $45.00 target price on the stock. Jones Trading began coverage on shares of ArriVent BioPharma in a report on Tuesday, May 20th. They set a “buy” rating and a $40.00 target price on the stock. Wall Street Zen cut shares of ArriVent BioPharma from a “hold” rating to a “strong sell” rating in a report on Thursday, May 22nd. Finally, B. Riley began coverage on shares of ArriVent BioPharma in a report on Thursday, March 20th. They set a “buy” rating and a $37.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, ArriVent BioPharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.29.

ArriVent BioPharma Stock Up 1.0%

AVBP stock opened at $21.20 on Monday. ArriVent BioPharma, Inc. has a fifty-two week low of $15.47 and a fifty-two week high of $36.37. The firm’s 50-day simple moving average is $19.28 and its 200 day simple moving average is $23.57. The stock has a market cap of $725.32 million, a PE ratio of -5.62 and a beta of 1.47.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($1.24). Equities analysts forecast that ArriVent BioPharma, Inc. will post -2.74 EPS for the current fiscal year.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.